We are live on ! Find out more
SAM

Sectoral Asset Management Portfolio holdings

AUM $121M
1-Year Est. Return 73.47%
This Fund
S&P 500
This Quarter Est. Return
+7.82%
1 Year Est. Return
+73.47%
3 Year Est. Return
+165.77%
5 Year Est. Return
+169.27%
10 Year Est. Return
+1,136.49%
AUM
$968M
AUM Growth
-$1.1B
Cap. Flow
-$1.16B
Cap. Flow %
-120.21%
Top 10 Hldgs %
41.41%
Holding
89
New
8
Increased
13
Reduced
37
Closed
25

Top Buys

Rank Stock Value
1
PFE icon
Pfizer
PFE
+$40.1M
2
ABMD
Abiomed Inc
ABMD
+$24.4M
3
GBT
Global Blood Therapeutics, Inc.
GBT
+$19.9M
4
ADPT
Adeptus Health Inc
ADPT
+$10.4M
5
TDOC icon
Teladoc Health
TDOC
+$5.7M

Top Sells

Rank Stock Value
1
CELG
Celgene Corp
CELG
+$112M
2
AMGN icon
Amgen
AMGN
+$102M
3
GILD icon
Gilead Sciences
GILD
+$102M
4
BMRN icon
BioMarin Pharmaceuticals
BMRN
+$84.5M
5
REGN icon
Regeneron Pharmaceuticals
REGN
+$83.9M

Sector Composition

Rank Sector Weight
1 Healthcare 94.16%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
LCI
51
DELISTED
Lannett Company, Inc.
LCI
$2.44M 0.25%
25,673
-6,816
-21% -$583K
NDRM
52
DELISTED
NeuroDerm Ltd. Ordinary Shares
NDRM
$1.71M 0.18%
+104,971
New +$1.77M
RDY icon
53
Dr. Reddy's Laboratories
RDY
$10.5B
$1.65M 0.17%
160,775
-299,750
-65% -$2.75M
SAGE
54
DELISTED
Sage Therapeutics
SAGE
$1.57M 0.16%
52,250
-368,834
-88% -$12.3M
AERI
55
DELISTED
Aerie Pharmaceuticals
AERI
$1.56M 0.16%
+88,400
New +$1.43M
AGIO icon
56
Agios Pharmaceuticals
AGIO
$2.36B
$1.51M 0.16%
+36,100
New +$1.78M
NTLA icon
57
Intellia Therapeutics
NTLA
$1.59B
$1.47M 0.15%
+123,159
New +$3.28M
SRRA
58
DELISTED
Sierra Oncology, Inc. Common Stock
SRRA
$1.36M 0.14%
5,042
-23,385
-82% -$4.46M
AVXS
59
DELISTED
AveXis, Inc. Common Stock
AVXS
$976K 0.1%
25,672
-271,928
-91% -$9.2M
ACAD icon
60
Acadia Pharmaceuticals
ACAD
$4.38B
$960K 0.1%
29,582
-661,118
-96% -$22.1M
CBPO
61
DELISTED
China Biologic Products Holdings, Inc.
CBPO
$626K 0.06%
5,890
– –
MCRB icon
62
Seres Therapeutics
MCRB
$51.6M
$598K 0.06%
+1,030
New +$604K
ALNY icon
63
Alnylam Pharmaceuticals
ALNY
$35.7B
$555K 0.06%
+10,000
New +$630K
AMGN icon
64
Amgen
AMGN
$198B
– –
-682,797
Closed -$102M
AMPH icon
65
Amphastar Pharmaceuticals
AMPH
$871M
– –
-38,905
Closed -$467K
ASND icon
66
Ascendis Pharma A/S
ASND
$17.1B
– –
-31,100
Closed -$577K
BIIB icon
67
Biogen
BIIB
$30.4B
– –
-234,572
Closed -$61.1M
EW icon
68
Edwards Lifesciences
EW
$49.4B
– –
-331,623
Closed -$9.75M
IONS icon
69
Ionis Pharmaceuticals
IONS
$8.99B
– –
-433,300
Closed -$17.5M
IRWD icon
70
Ironwood Pharmaceuticals
IRWD
$635M
– –
-12,806
Closed -$117K
NKTR icon
71
Nektar Therapeutics
NKTR
$2.31B
– –
-851
Closed -$175K
NVS icon
72
Novartis
NVS
$293B
– –
-138,166
Closed -$8.97M
PRGO icon
73
Perrigo
PRGO
$1.48B
– –
-17,030
Closed -$2.18M
REGN icon
74
Regeneron Pharmaceuticals
REGN
$70.9B
– –
-232,770
Closed -$83.9M
TGTX icon
75
TG Therapeutics
TGTX
$8.4B
– –
-1,521,667
Closed -$13M
1 2
3
4

Similar funds

RIP
Reliant Investment Partners Pinehurst, North Carolina $121M AUM 34.77% 1-Year Est. Return
CCM
Chicago Capital Management Chicago, Illinois $121M AUM 74.36% 1-Year Est. Return
LFWA
LiftPoint Family Wealth Advisors Far Hills, New Jersey $121M AUM
FWA
Fulcrum Wealth Advisors Bellevue, Washington $121M AUM
CF
Conquis Financial Milbrae, California $121M AUM 16.22% 1-Year Est. Return
WIM
Wiregrass Investment Management Thomasville, Georgia $121M AUM
MW
Merited Wealth North Bay Village, Florida $121M AUM
AFC
Avise Financial Cooperative Los Angeles, California $121M AUM

Sectoral Asset Management's Q2 2016 Portfolio in Review

As of Q2 2016, Sectoral Asset Management held 89 positions worth $968M, down 53% from $2.07B the previous quarter. Its ten largest holdings account for 41% of the portfolio.

Sectoral Asset Management withdrew a net $1.16B in Q2 2016, closing 25 positions and reducing 37 holdings. Its most notable exit was Amgen, an estimated $102M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 94% of assets, down from 95% a quarter earlier.

Against the trend, Sectoral Asset Management opened a new position in Pfizer worth $42M.

  • Sectoral Asset Management's largest Q2 2016 buy was Pfizer: 1,256,716 shares worth $42M.
  • Sectoral Asset Management added most to Abiomed Inc in Q2 2016, an estimated $24.4M increase.
  • Sectoral Asset Management's biggest Q2 2016 reduction was Celgene Corp, cutting an estimated $112M.
  • Sectoral Asset Management fully exited Amgen in Q2 2016, selling an estimated $102M.
  • Sectoral Asset Management's ten largest holdings make up 41% of its $968M portfolio in Q2 2016.
  • Sectoral Asset Management opened 8 new positions and closed 25 in Q2 2016.
  • Sectoral Asset Management's portfolio value fell 53% quarter-over-quarter to $968M.

Based on Sectoral Asset Management's 13F filing for Q2 2016, filed 12 Aug 2016.